Seewann HL - Search Results

1

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.

Ludwig H, Cohen AM, Huber H, Nachbaur D, Jungi WF, Senn H, Günczler P, Schüller J, Eckhardt S, Seewann HL, et al. Ludwig H, et al. Among authors: seewann hl. Eur J Cancer. 1991;27 Suppl 4:S40-5. doi: 10.1016/0277-5379(91)90570-4. Eur J Cancer. 1991. PMID: 1799476 Clinical Trial.

2

Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.

Ludwig H, Cohen AM, Polliack A, Huber H, Nachbaur D, Senn HJ, Morant R, Eckhardt S, Günczler P, Seewann HL, et al. Ludwig H, et al. Among authors: seewann hl. Ann Oncol. 1995 May;6(5):467-76. doi: 10.1093/oxfordjournals.annonc.a059217. Ann Oncol. 1995. PMID: 7669712 Free article. Clinical Trial.

3

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside.

Thaler J, Fluckinger T, Huber H, Lang A, Abbrederis C, Seewann H, Silly H, Baldinger C, Duba C, Huber C, et al. Thaler J, et al. Leuk Res. 1993 Aug;17(8):711-5. doi: 10.1016/0145-2126(93)90079-z. Leuk Res. 1993. PMID: 8355515

4

Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.

Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Sill H, Lang A, Falk M, Duba C, Utermann G, Kühr T, Aulitzky W, Huber C. Thaler J, et al. Ann Hematol. 1996 Jun;72(6):349-55. doi: 10.1007/s002770050185. Ann Hematol. 1996. PMID: 8767103 Clinical Trial.

5

Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b.

Seewann HL, Zikulnig R, Gallhofer G, Schmid C. Seewann HL, et al. Eur J Cancer. 1991;27 Suppl 4:S58-62; discussion S62-3. doi: 10.1007/978-3-642-75510-1_71. Eur J Cancer. 1991. PMID: 1799482

6

Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.

Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M. Thaler J, et al. Leuk Res. 1997 Jan;21(1):75-80. doi: 10.1016/s0145-2126(96)00084-7. Leuk Res. 1997. PMID: 9029189 Clinical Trial.

7

Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.

Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H, et al. Thaler J, et al. Semin Hematol. 1993 Jul;30(3 Suppl 3):17-9. Semin Hematol. 1993. PMID: 8235697 Clinical Trial. No abstract available.

8

Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.

Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Hilbe W, et al. Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8. doi: 10.3109/10428190109097753. Leuk Lymphoma. 2001. PMID: 11911409 Clinical Trial.

9

[Recombinant interferon alpha-2c in Ph-positive chronic myeloid leukemia. Results of a multicenter phase II study].

Thaler J, Kühr T, Gastl G, Huber H, Duba C, Kemmler G, Gattringer C, Fluckinger T, Niederwieser D, Seewann H, et al. Thaler J, et al. Dtsch Med Wochenschr. 1991 May 10;116(19):721-8. doi: 10.1055/s-2008-1063670. Dtsch Med Wochenschr. 1991. PMID: 2026104 Clinical Trial. German.

10

Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.

Fridrik MA, Jäger G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubauer M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W. Fridrik MA, et al. Among authors: seewann hl. Eur J Cancer. 1998 Sep;34(10):1560-4. doi: 10.1016/s0959-8049(98)00140-3. Eur J Cancer. 1998. PMID: 9893628 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page